<DOC>
	<DOCNO>NCT02891239</DOCNO>
	<brief_summary>This open-label , multi-center study . Subjects study receive eight ( 8 ) treatment 11±5 week ( 6-16 week ) interval , PicoWay device use 785 nm wavelength alone combined 1064 nm 532 nm wavelength . Subjects return one follow‐up ( FU ) visit clinic 8 week follow last treatment .</brief_summary>
	<brief_title>785nm Picosecond Laser Treatment Benign Pigmented Lesions</brief_title>
	<detailed_description>This study prospective clinical study demonstrate safety efficacy PicoWay device benign pigment lesion treatment . Up total 60 healthy candidate , seek treatment/clearance benign pigment lesion , enrol 3 participate study site . Subjects receive eight ( 8 ) PicoWay treatment 11±5 ( 6-16 ) week 's interval . Prior consecutive treatment , investigator decide , base degree clearance assessment , subject undergo additional treatment proceed 8-weeks follow-up ( FU ) visit treatment .</detailed_description>
	<criteria>1 . Healthy female male subject 18 70 year age 2 . Fitzpatrick skin type IVI 3 . Presence unwanted benign pigment lesion include limited solar lentigo , freckle , café au lait , melasma , Nevis Ota , Nevus Ito hyperpigmentation . Multiple lesion treat . 4 . Willing receive propose PicoWay treatment comply study ( protocol ) requirement remove unwanted benign pigment lesion . 5 . Willing photograph image take treated area use evaluation , publication presentation ( subject identity mask ) . 6 . For female subject : pregnant lactate either postmenopausal , surgically sterilize , use medically acceptable form birth control least 3 month prior enrollment ( i.e. , oral contraceptive , contraceptive implant , barrier method spermicide abstinence ) 7 . Informed consent process complete subject consent sign . 1 . Pregnant plan become pregnant , give birth le 3 month ago , and/or breast feeding 2 . Hypersensitivity light exposure 3 . Taking medication ( ) sunlight contraindication 4 . Active sun tan 5 . Suffering significant skin condition treat area inflammatory skin condition , include , limited , open laceration abrasion , hidradenitis , dermatitis treatment area prior treatment ( duration resolution per Investigator 's discretion ) treatment course 6 . History squamous cell carcinoma melanoma 7 . History keloid scarring , abnormal wound heal / prone bruise 8 . Use oral isotretinoin ( Accutane® ) within 12 month initial treatment plan use course study . Note : Skin must regain normal degree moisture prior treatment , e.g. , lack noticeable skin flaking , skin peel skin surface roughness 9 . History immunosuppression/immune deficiency disorder ( include HIV infection AIDS ) currently use immunosuppressive medication 10 . Known allergy lidocaine , tetracaine , Xylocaine epinephrine 11 . Has laser procedure , peel use lighten creams area treat past six month 12 . Subjects pigment lesion consider acceptable study doctor condition , study doctor 's opinion , would make unsafe treat 13 . As per investigator 's discretion , physical mental condition might make unsafe subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>laser treatment</keyword>
</DOC>